InVivo Therapeutics (NSDQ:NVIV) has registered for a new offering of shares and warrants that could bring in approximately $11 million, according to an SEC filing. In the offering, the company will look to float approximately 1.5 million shares and 1.5 million Series A warrants at $7.40 per share. InVIvo Therapeutics has not yet announced the exercise […]
UPDATE: InVivo shares surge on release of 6-month results from cancelled Inspire trial
InVivo Therapeutics (NSDQ:NVIV) today has seen shares rise as much as 75% after it released complete six-month results from the company’s Inspire study of its neuro-spinal scaffold, which it ended in January after halting enrollment last July. Results were presented by Dr. Stuart Lee of Vidant Health at the 2018 AANS meeting yesterday, the Cambridge, Mass.-based […]
InVivo Therapeutics registers $8m offering
InVivo Therapeutics (NSDQ:NVIV) today registered for an upcoming offering, looking to raise approximately $8 million, according to an SEC filing. In the offering, the Cambridge, Mass.-based company will look to offer shares of common stock and Series A warrants. The offering is slated to include a 45-day underwriter’s option for the purchase of additional shares, according […]
InVivo plans 1-for-25 reverse stock split
InVivo Therapeutics (NSDQ:NVIV) said today it is initiating a 1-for-25 reverse split of its stock, looking to put a single share in the hands of its shareholders for every 25 shares they previously owned. The move will reduce the company’s authorized shares from 100 million to just four million, the Cambridge, Mass.-based company said, and is […]
InVivo wins FDA nod for new pivotal trial of its neuro-spinal scaffold
InVivo Therapeutics (NSDQ:NVIV) said today it won FDA investigational device exemption for a new pivotal trial of its neuro-spinal scaffold after ending the previous Inspire study of the device in January. The Cambridge, Mass.-based company’s neuro-spinal scaffold is a novel, biodegradable device designed to be surgically implanted following acute spinal cord injuries to act as a physical […]
Facing legal woes, PixarBio takes aim at InVivo
PixarBio (OTC:PXRB) faces its own legal problems: a possible lawsuit by the SEC, legal action by a disgruntled employee who is demanding unpaid wages and former landlords looking for $1.8 million in unpaid rent. But the 7-person biotech is also looking to launch some litigation of its own, according to a recent document it filed with the SEC […]
InVivo Therapeutics lifts Toselli to permanent prez, CEO | Personnel Moves February 6, 2018
InVivo Therapeutics (NSDQ:NVIV) said yesterday it made Dr. Richard Toselli’s spot in the corner office permanent, lifting him from acting CEO to prez and CEO. Dr. Toselli will maintain his position on the company’s board and as its chief medical officer, the position he was given when he joined the company last July. Prior to joining InVivo, […]
InVivo Therapeutics inks $15m share purchase agreement
InVivo Therapeutics (NSDQ:NVIV) said today it inked a stock purchase agreement with Lincoln Park Capital Fund to sell up to $15 million in shares over a two-year period. The new agreement comes with conditions and limitations, including giving the rights to InVivo to control the timing and amount of sales of stock and that the purchase […]
InVivo to end Inspire trial despite meeting primary endpoint, plans new study
InVivo Therapeutics (NSDQ:NVIV) today released updated results from the Inspire study of its neuro-spinal scaffold but said that it would not be reopening enrollment, which it paused last July, and is instead looking to a new randomized controlled trial to supplement the results. The Cambridge, Mass.-based company said that 43.8% of the 16 living patients in the […]
Zimmer Biomet lures Medtronic vet Hanson to CEO spot | Personnel Moves December 19, 2017
Zimmer Biomet (NYSE:ZBH) said today it tapped former Medtronic (NYSE:MDT) exec VP Bryan Hanson as its new prez and CEO, replacing interim CEO Daniel Florin who will continue on as CFO and senior VP. A 20-year veteran of medical devices, Hanson operated most recently as group president of Fridley, Minn.-based Medtronic’s approximately $9 billion minimally invasive […]
InVivo pulls trigger on $2m warrant exchange
InVivo Therapeutics (NSDQ:NVIV) said today it exchanged outstanding warrants, issued as part of a financing in 2014, for 2 million new shares of common stock. The exchange is worth approximately $2.4 million, given InVivo’s current share price of $1.20 as of 10:44 a.m. EDT. InVivo said it negotiated individual exchange agreements with warrant holders, and that […]
- « Previous Page
- 1
- 2
- 3
- 4
- …
- 17
- Next Page »
MassDevice Network
@MassDevice
LinkedIn
YouTube